Literature DB >> 2294993

Pure red cell aplasia of long duration complicating major ABO-incompatible bone marrow transplantation.

J P Gmür1, J Burger, A Schaffner, K Neftel, O Oelz, D Frey, M Metaxas.   

Abstract

In 3 of 15 consecutive patients receiving a human leukocyte antigen (HLA)-identical but major ABO incompatible bone marrow transplant (BMT), pure red cell aplasia (PRA) lasting 5 to 8 months was observed. Titers of the incompatible anti-A agglutinin before infusion of the red blood cell (RBC)-depleted BMT was very high in one, and in the usual range in two patients. Decrease of agglutinin titers during the first 4 weeks after BMT were comparable between PRA patients and those of ABO-incompatible BMT recipients with timely RBC recovery. However, in PRA patients, agglutinin titers rose again and remained elevated for 19 to 28 weeks. RBC engraftment and reticulocyte recovery ultimately occurred spontaneously and coincided with the decrease of agglutinin titers below 16. These observations indicate that PRA is antibody-dependent in this setting. Furthermore, it is conceivable that cyclosporine facilitates recipient-derived antibody synthesis after major ABO-incompatible BMT.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2294993

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

Review 1.  Tolerance by transplantation: how much is enough, how much is too much?

Authors:  J L Platt
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

Review 2.  The processing of stem cell concentrates from the bone marrow in ABO-incompatible transplants: how and when.

Authors:  Nicola Daniele; Maria Cristina Scerpa; Cecilia Rossi; Alessandro Lanti; Gaspare Adorno; Giancarlo Isacchi; Francesco Zinno
Journal:  Blood Transfus       Date:  2013-11-21       Impact factor: 3.443

3.  Oral High Dose Dexamethasone for Pure Red Cell Aplasia Following ABO-Mismatched Allogeneic Peripheral Blood Stem Cell Transplantation: A Case Report.

Authors:  Sanjeev Kumar Sharma; Suman Kumar; Narendra Agrawal; Pravas Mishra; Tulika Seth; Manoranjan Mahapatra
Journal:  Indian J Hematol Blood Transfus       Date:  2013-06-09       Impact factor: 0.900

4.  Haemolysis, pure red cell aplasia and red cell antibody formation associated with major and bidirectional ABO incompatible haematopoietic stem cell transplantation.

Authors:  Gordana Tomac; Ines Bojanić; Sanja Mazić; Ivana Vidović; Mirela Raos; Branka Golubić Ćepulić; Ranka Serventi Seiwerth; Jadranka Kelečić; Boris Labar
Journal:  Blood Transfus       Date:  2017-04-19       Impact factor: 3.443

Review 5.  Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question.

Authors:  Javier Marco-Ayala; Inés Gómez-Seguí; Guillermo Sanz; Pilar Solves
Journal:  Bone Marrow Transplant       Date:  2020-11-14       Impact factor: 5.483

Review 6.  Parvovirus B19 infection and bone marrow transplantation.

Authors:  N Frickhofen; R Arnold; B Hertenstein; M Wiesneth; N S Young
Journal:  Ann Hematol       Date:  1992-06       Impact factor: 3.673

Review 7.  Transfusion medicine problems and solutions for the pediatric hematologist/oncologist.

Authors:  Naomi L C Luban; Eileen McBride; Jason C Ford; Sumit Gupta
Journal:  Pediatr Blood Cancer       Date:  2012-01-11       Impact factor: 3.167

8.  Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins.

Authors:  Georg Stussi; Jörg Halter; Eveline Bucheli; Piero V Valli; Lutz Seebach; Jürg Gmür; Alois Gratwohl; Urs Schanz; Jakob R Passweg; Jörg D Seebach
Journal:  Haematologica       Date:  2009-01-14       Impact factor: 9.941

Review 9.  A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation.

Authors:  James L Gajewski; Viviana V Johnson; S Gerald Sandler; Antoine Sayegh; Thomas R Klumpp
Journal:  Blood       Date:  2008-06-26       Impact factor: 22.113

10.  Bone marrow transplantation in sickle cell anaemia.

Authors:  C Vermylen; G Cornu; M Philippe; J Ninane; A Borja; D Latinne; A Ferrant; J L Michaux; G Sokal
Journal:  Arch Dis Child       Date:  1991-10       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.